Non-Formulary Medications: Documenting Medical Necessity

James Wong — Founder & CEO, LienScripts | March 26, 2026 | 8 min read

When insurance denies coverage for non-formulary medications, the physician's prescribing decision becomes powerful evidence of medical necessity. Learn how to document non-formulary prescriptions for PI settlement demands.

Non-Formulary Medications: Documenting Medical Necessity

A non-formulary medication — one that an insurance plan does not cover or places on a restrictive coverage tier — is prescribed when the treating physician determines that formulary alternatives are clinically inadequate for the patient's specific injury. This prescribing decision is itself powerful evidence of medical necessity because the physician chose a harder, more expensive path when easier options existed, documenting through their professional judgment that the patient's condition requires a specific medication that insurance formulary restrictions cannot accommodate.

• Non-formulary prescribing occurs when the treating physician determines formulary alternatives (preferred by insurance) are clinically inferior for the patient's specific condition
• The prescribing decision documents that the physician evaluated alternatives and found them inadequate — a medical necessity determination in practice
• Common non-formulary PI medications include branded neuropathic agents, newer sleep medications, specific muscle relaxant formulations, and specialty compounds
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report explaining the clinical rationale for non-formulary medication selection
• Pharmacy liens bypass formulary restrictions entirely, ensuring patients receive the physician's preferred medication

What Makes a Medication Non-Formulary

Insurance formularies are tiered lists of medications organized by the insurer's cost preferences:

• Tier 1 (Preferred generics): Lowest copay, insurer's preferred options
• Tier 2 (Non-preferred generics/preferred brands): Higher copay
• Tier 3 (Non-preferred brands): Highest copay; may require prior authorization
• Non-formulary: Not covered at all; patient pays full retail price

Formulary placement is driven primarily by the insurer's negotiated rebates and cost structure — not by clinical superiority. A Tier 1 medication is not necessarily the best medication for the patient; it is the cheapest medication for the insurer.

According to James Wong, PharmD, founder of LienScripts, "Formulary tiers reflect insurance economics, not clinical quality. When a physician prescribes a non-formulary medication, they are saying the insurance company's preferred options are not clinically appropriate for this patient. That is a medical necessity determination documented through the prescribing act itself."

[!KEY] Non-formulary prescribing is a physician's documented determination that insurance-preferred alternatives are clinically inadequate for the patient's specific condition — the prescribing decision itself constitutes medical necessity evidence because the physician chose the harder path when easier options existed.

Why Physicians Prescribe Non-Formulary Medications in PI Cases

Pharmacokinetic Superiority

Some non-formulary medications have pharmacokinetic properties that make them clinically superior for specific conditions:

• Pregabalin (Lyrica) vs. formulary gabapentin — pregabalin has linear, predictable absorption unlike gabapentin's saturable absorption that becomes unreliable at higher doses (FDA label, NDA 021446). For neuropathic pain requiring reliable dose-response, the physician may determine pregabalin is necessary.

• Extended-release formulations vs. immediate-release generics — ER formulations provide steady blood levels that prevent breakthrough symptoms. When the generic IR version causes unacceptable peak-trough fluctuations, the ER formulation is medically necessary.

Side Effect Profile

• Celecoxib vs. formulary ibuprofen — for patients with GI risk factors, the COX-2 selective agent avoids the GI bleeding risk of non-selective NSAIDs (PubMed PMID: 11036118)
• Newer sleep agents vs. formulary zolpidem — orexin antagonists offer a different safety profile with less abuse potential and better sleep architecture preservation

Unique Mechanism of Action

Some non-formulary medications have mechanisms that formulary alternatives simply do not replicate:

• Orexin antagonists (lemborexant, daridorexant) — no formulary equivalent exists; these work through a unique mechanism unavailable in older sleep medications
• Specific biologic agents — when the formulary TNF inhibitor has failed, a non-formulary IL-17 or IL-23 inhibitor may be the only effective option
• Topical compound formulations — no commercial equivalent exists for multi-ingredient compounds

[!TIP] When building the demand narrative, identify exactly why the non-formulary medication was chosen over formulary alternatives. The physician's clinical reasoning — documented in the medical record at the time of prescribing — is the key evidence. Request the specific progress note where the non-formulary decision was made.

The Insurance Denial as Evidence

When insurance denies a non-formulary medication, the denial letter and the physician's response create an evidentiary record:

1. The prescription — documents the physician's clinical determination
2. The insurance denial — documents that the medication is not covered (formulary restriction, not clinical rejection)
3. The appeal letter (if filed) — documents the physician's clinical reasoning in detail
4. Step therapy failures (if required) — documents that formulary alternatives were tried and failed

This paper trail is valuable evidence for the demand package. It shows a physician fighting against insurance restrictions to get their patient the medication they need — the opposite of casual or unnecessary prescribing.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "An insurance denial of a non-formulary medication is actually helpful for the PI case. It creates a documented record of the physician asserting medical necessity against the insurer's cost preferences. When we see this pattern in the pharmacy records, the MERIT report highlights it as evidence of the medication's clinical importance."

[!KEY] An insurance denial of a non-formulary medication creates an evidentiary paper trail — the physician's prescription, the insurer's denial, and any appeal or step-therapy documentation — that together constitute a robust medical necessity record more detailed than routine prescribing ever produces.

Pharmacy Lien Solutions for Non-Formulary Medications

A pharmacy lien through LienScripts resolves the non-formulary problem completely:

No Formulary Restrictions

The LienScripts pharmacy network does not operate on insurance formulary tiers. Every medication the physician prescribes is dispensed at zero upfront cost, regardless of formulary status. The clinical determination drives the dispensing, not the insurer's cost preferences.

No Step Therapy Requirements

Insurance often requires patients to try and fail on formulary alternatives before covering non-formulary medications. This "step therapy" protocol delays effective treatment and creates a confusing medication switching history. On lien, the physician prescribes directly — no mandated trials of inferior alternatives.

Complete Documentation

Every non-formulary medication dispensed on lien is documented in the LienScripts system with date, prescriber, medication, and quantity. The MERIT report provides the clinical narrative explaining why the specific non-formulary medication was necessary.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages.

Documenting Non-Formulary Necessity in the Demand

What to Include

1. The physician's prescribing rationale — why this specific medication, not a formulary alternative
2. Clinical differences between the prescribed medication and formulary options — pharmacokinetic, safety, or mechanism-of-action distinctions
3. Insurance denial documentation (if applicable) — showing the denial was formulary-based, not clinical
4. Treatment outcomes — how the patient responded to the non-formulary medication
5. MERIT report annotations — pharmacist-verified clinical narrative supporting the selection

What to Avoid

Do not argue that the non-formulary medication is simply "better" without specificity. Instead, document the clinical reason it was necessary for this patient's specific condition: the GI risk that precluded ibuprofen, the absorption variability that made gabapentin unreliable, the mechanism that no formulary agent provides.

Adjuster Objections and Responses

"A formulary alternative was available and would have been cheaper." Counter: The treating physician evaluated formulary alternatives and determined they were clinically inadequate for this patient's condition. Formulary placement reflects insurer economics, not clinical superiority. The physician's medical judgment — not the insurer's cost preferences — determines appropriate treatment.

"The patient should have used step therapy to get the non-formulary medication covered." Counter: Step therapy requires the patient to trial and fail on inferior medications before receiving the one their physician prescribed. This delays effective treatment, creates unnecessary suffering, and produces a confusing medication history. The pharmacy lien ensured immediate access to the clinically indicated medication.

"There is no proof the formulary alternative would not have worked." Counter: The prescribing physician's clinical judgment that the formulary alternative was inadequate for this patient is itself the proof. Physicians do not prescribe harder-to-obtain, more expensive medications without clinical justification.

[!TIP] If the patient initially tried a formulary medication that proved inadequate before switching to the non-formulary option, this documented failure is the strongest possible evidence. Include the dates, duration, and documented reason for switching in the demand narrative.

Related Resources

• Insurance Denial and Medication Access
• Prior Authorization Delays and Pharmacy Liens
• Treatment Gaps and Medication Access
• How LienScripts Works